source
- Gilead places partial clinical hold on two KITE-753 CAR-T trials in diffuse large B-cell lymphomaGilead announced on its third-quarter earnings call that it has placed a partial clinical hold on two CAR-T trials for KITE-753 targeting diffuse large B-cell lymphoma (DLBCL). The hold affects th…
- Merck R&D chief says company has outpaced rivals with its sac-TMT cancer platformDean Li, the head of Merck Research Laboratories, said the company believes its sac-TMT cancer program gives it a competitive edge over other firms developing next-generation oncology therapies. T…